{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Neoplasm", "query": { "condition": "Cervical Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 4054, "total_pages": 406, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T18:41:14.333Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04459273", "title": "Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Hepatocellular Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Pleural Neoplasm", "Malignant Skin Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Thymus Neoplasm", "Neuroendocrine Neoplasm", "Thyroid Gland Carcinoma", "Urothelial Carcinoma", "Cancer of Unknown Primary Site" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-08-27", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459273" }, { "nct_id": "NCT04268329", "title": "Evaluating the Use of an Informational Head and Neck Cancer Website.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Educational website", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2016-08-16", "completion_date": "2020-06-18", "has_results": false, "last_update_posted_date": "2021-04-09", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04268329" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT03970083", "title": "A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gynecologic Cancer", "Cervical Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2019-07-16", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970083" }, { "nct_id": "NCT02538510", "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Salivary Gland Carcinoma", "Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary", "Stage III Major Salivary Gland Carcinoma", "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage III Nasopharyngeal Carcinoma", "Stage IV Nasopharyngeal Carcinoma", "Stage IVA Major Salivary Gland Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Major Salivary Gland Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Major Salivary Gland Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-10-08", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538510" }, { "nct_id": "NCT01266460", "title": "Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Recurrent Cervical Carcinoma" ], "interventions": [ { "name": "Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2011-05-23", "completion_date": "2018-10-02", "has_results": true, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266460" }, { "nct_id": "NCT02351479", "title": "Hula, a Physical Activity Intervention for Female-Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Physical Activity", "Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Hula", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 73, "start_date": "2013-09", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT02351479" }, { "nct_id": "NCT06980103", "title": "Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Decision Aid", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-08-06", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Falls Church, Virginia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980103" }, { "nct_id": "NCT06459180", "title": "A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Tisotumab Vedotin", "type": "BIOLOGICAL" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 686, "start_date": "2024-07-24", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 38, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06459180" }, { "nct_id": "NCT00045669", "title": "Imatinib Mesylate in Treating Patients With Salivary Gland Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Health Network, Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2002-07", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-07-22T18:41:14.333Z", "location_count": 14, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045669" } ] }